Result: The TAMs M41L, D67N/E/G and K219Q/E/N/R and the T215 revertant mutations (T215C/D/E/S/I/V) were the most common non-major transmitted NRTI DRMs.
HIV-1 subtype characteristics of infected persons living in southwestern Greece.
Result: The 22 cases experiencing virologic failure presented with the following DRMs: M46I, F53LY, I54LTV, G73ST, L76V, V82AT, I84V, I185V, N88D, and L90M for PIs; L100I, K103NS, V179F Y181C, G190AS, V106A, K103N, and P225H for NNRTIs; and
Characterization of two HIV-1 infectors during initial antiretroviral treatment, and the emergence of phenotypic resistance in reverse transcriptase-associated mutation patterns.
Discussion: This report indicated that K70R was followed by T215Y and accumulated the cluster mutation M41L/D67N/K70R/T215Y (K219Q), but herein we observed no cluster.
The Evolving Genotypic Profile of HIV-1 Mutations Related to Antiretroviral Treatment in the North Region of Brazil.
Result: Taking into account multiple mutations together, the thymidine analog mutations (TAM) pathway 1 (including M41L, L210W, and T215Y) was selected in 40.8% of the patients, whereas TAM-2 (including D67N, K70R, T215F, and 58 K219Q/E) was present in 42.2%.
Result: The M41L, D67N, V118I, L210W,
Discussion: Resistance to NRTIs in multifailed patients was related to the presence of the TAMs M41L, D67N, L210W, and K219Q.
Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study.
Discussion: Despite the extensive use of thymidine analogues like AZT or D4T in Ethiopia and unlike previous similar studies, TAMs characterized by the mutations M41L, L210W, T215Y (TAM-path 1) and D67N, K70R, T215F, K219Q/E (TAM-path 2) were lacking in the current study indicating a recent period of virological failure.
High Prevalence of HIV Low Abundance Drug-Resistant Variants in a Treatment-Naive Population in North Rift Kenya.
PMID: 26414430
2015
AIDS research and human retroviruses
Abstract: The most prevalent mutation was NRTI position K219Q/R (11/46, 24%) followed by NRTI M184V (5/46, 11%) and NNRTI K103N (4/46, 9%).
Outcome of patients on second line antiretroviral therapy under programmatic condition in India.
Abstract: HIV-1 resistance to zidovudine [AZT (azidothymidine)] is associated with selection of the mutations M41L, D67N, K70R, L210W, T215F/Y and K219Q/E in RT (reverse transcriptase).
Introduction: HIV-1 resistance to AZT is associated with selection of the thymidine analog mutations (TAMs) M41L, D67N, K70R, L210W, T215F/Y and K219Q/E in RT.
Result: Consistent with previously published data, we found that RTs
2014 Update of the drug resistance mutations in HIV-1.
Discussion: Mutations known to be selected by TAMs (ie, M41L, D67N, K70R, L210W, T215Y/F, and K219Q/E) also confer reduced susceptibility to all currently approved nRTIs.
Discussion: The presence of 3 of the following mutations:M41L, D67N, L210W, T215Y/F, K219Q/E:is associated with resistance to didanosine.
Molecular basis of the association of H208Y and thymidine analogue resistance mutations M41L, L210W and T215Y in the HIV-1 reverse transcriptase of treated patients.
Abstract: Thymidine analogue resistance mutations (TAMs) in HIV-1 reverse transcriptase (RT) associate in two clusters: (i) TAM1 (M41L, L210W and T215Y) and TAM2 (D67N, K70R, K219E/Q, and sometimes T215F).
HIV mutation literature information.
PMID: 
2015
PloS one
Browser Board
Co-occurred Entities
Filtrator
ViMRT